Peptide Comparison
Epitalon vs Vesilute
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Epitalon has stronger documented evidence (Russia-Clinical + Animal Studies) than Vesilute (Russian Research) while both occupy the khavinson class. When clinical-evidence tier is the deciding factor, Epitalon is the safer pick. Vesilute may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Epitalon | Vesilute | |
|---|---|---|
| Class | Khavinson pineal tetrapeptide; longevity peptide | Khavinson short peptide bioregulator |
| Drug class | Longevity | Tissue Repair |
| Mechanism | Activates telomerase gene expression; modulates pineal function and melatonin secretion | Membrane-penetrant Glu-Asp dipeptide; modulates gene expression in bladder urothelium and smooth muscle |
| Route | SC / Oral | Oral |
| Half-life | ~20 min | Short (minutes) |
| Dosage (research) | 5 mg SC daily for 10-20 day cycles 2x yearly (Khavinson Russian gerontology starting dose, range up to 10 mg/day per published protocols) | Oral capsule 1-2x daily |
| Evidence tier | Russia-Clinical + Animal Studies | Russian Research |
| Research depth | 155 indexed | 1 indexed |
| Availability | Research | Research |
| Reported risks | Limited Western trials; Russian-origin data | Very limited data; no English-indexed primary literature |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Epitalon or Vesilute?
Epitalon has stronger documented evidence (Russia-Clinical + Animal Studies) than Vesilute (Russian Research) while both occupy the khavinson class. When clinical-evidence tier is the deciding factor, Epitalon is the safer pick. Vesilute may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Epitalon and Vesilute?
Epitalon is classed as Khavinson pineal tetrapeptide; longevity peptide; Vesilute is classed as Khavinson short peptide bioregulator. Reported mechanism: Epitalon, Activates telomerase gene expression; modulates pineal function and melatonin secretion; Vesilute, Membrane-penetrant Glu-Asp dipeptide; modulates gene expression in bladder urothelium and smooth muscle. Reported half-life: Epitalon, ~20 min; Vesilute, Short (minutes). Routes in published studies: Epitalon, SC / Oral; Vesilute, Oral.
Which has stronger evidence, Epitalon or Vesilute?
Epitalon has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Epitalon is graded Russia-Clinical + Animal Studies, with 7 cited sources on its reference page and 155 indexed studies. Vesilute is graded Russian Research, with 2 cited sources on its reference page and 1 indexed studies.
Which is more accessible, Epitalon or Vesilute?
Neither Epitalon nor Vesilute is an FDA-approved drug. Catalog status: Epitalon, Research; Vesilute, Research. Epitalon's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are Epitalon and Vesilute ever combined?
Epitalon and Vesilute appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…